Ameriprise Financial Inc. Has $373.24 Million Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Ameriprise Financial Inc. grew its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.6% in the third quarter, according to its most recent filing with the SEC. The fund owned 3,789,200 shares of the medical equipment provider’s stock after acquiring an additional 58,335 shares during the period. Ameriprise Financial Inc. owned 1.91% of Zimmer Biomet worth $373,239,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of ZBH. Schonfeld Strategic Advisors LLC increased its holdings in Zimmer Biomet by 3,633.7% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 464,250 shares of the medical equipment provider’s stock worth $45,729,000 after purchasing an additional 451,816 shares in the last quarter. Creative Planning boosted its stake in shares of Zimmer Biomet by 46.0% during the third quarter. Creative Planning now owns 45,899 shares of the medical equipment provider’s stock valued at $4,521,000 after purchasing an additional 14,454 shares in the last quarter. Credit Agricole S A acquired a new stake in shares of Zimmer Biomet during the third quarter valued at about $7,264,000. Raymond James Financial Inc. grew its holdings in shares of Zimmer Biomet by 7.9% during the third quarter. Raymond James Financial Inc. now owns 700,471 shares of the medical equipment provider’s stock worth $68,996,000 after purchasing an additional 51,025 shares during the last quarter. Finally, Amundi grew its holdings in shares of Zimmer Biomet by 12.6% during the third quarter. Amundi now owns 716,847 shares of the medical equipment provider’s stock worth $70,846,000 after purchasing an additional 80,190 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the completion of the transaction, the senior vice president directly owned 10,224 shares of the company’s stock, valued at approximately $967,803.84. This trade represents a 20.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.70% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ZBH. William Blair initiated coverage on Zimmer Biomet in a research note on Friday, February 20th. They issued a “market perform” rating for the company. Citigroup reissued a “buy” rating on shares of Zimmer Biomet in a report on Wednesday, February 11th. Wall Street Zen cut shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. TD Cowen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Monday, January 26th. Finally, Wells Fargo & Company lifted their price target on shares of Zimmer Biomet from $93.00 to $98.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 11th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $106.20.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $93.36 on Tuesday. The stock’s 50 day moving average is $92.42 and its 200 day moving average is $95.03. Zimmer Biomet Holdings, Inc. has a one year low of $84.59 and a one year high of $114.44. The firm has a market cap of $18.27 billion, a P/E ratio of 26.37, a P/E/G ratio of 1.90 and a beta of 0.58. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.10.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The business had revenue of $2.24 billion during the quarter, compared to the consensus estimate of $2.22 billion. During the same quarter in the prior year, the firm posted $2.31 EPS. The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is presently 27.12%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.